The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Takeda Pharmaceutical Co ADR shares valued at $284,951 were purchased by Giles Richard Platford on Aug 23 ’24. At $14.94 per share, Giles Richard Platford acquired 19,073 shares.
As published in a research note from Morgan Stanley on April 02, 2025, Takeda Pharmaceutical Co ADR [TAK] has been rated up from an Equal-weight to an Overweight. Analysts at BofA Securities upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in mid March. As of July 19, 2022, Cowen has increased its “Market perform” rating to a “an Outperform” for TAK. Earlier on October 07, 2021, Morgan Stanley downgraded its rating. Their new recommendation was “an Equal-weight” for TAK stock which previously was a “an Overweight”.
Analyzing TAK Stock Performance
During the last five days, there has been a surge of approximately 0.72%. Over the course of the year, Takeda Pharmaceutical Co ADR shares have jumped approximately 15.48%. Shares of the company reached a 52-week high of $15.37 on 04/03/25 and a 52-week low of $12.80 on 01/23/25. A 50-day SMA is recorded $14.78, while a 200-day SMA reached $14.09.
Support And Resistance Levels for Takeda Pharmaceutical Co ADR (TAK)
According to the 24-hour chart, there is a support level at 15.19, which, if violated, would cause prices to drop to 15.10. In the upper region, resistance lies at 15.34. The next price resistance is at 15.40. RSI (Relative Strength Index) is 60.64 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.44, which suggests the price will decrease in the coming days. Percent R is at 2.59%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
